Signature required: The transcriptional response to tuberculosis
Open Access
- 15 November 2021
- journal article
- editorial
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 218 (12)
- https://doi.org/10.1084/jem.20211665
Abstract
The majority of humans infected with Mycobacterium tuberculosis never experience clinical symptoms or signs, but predicting those who will remains out of reach. Here, we discuss recent studies that reveal patterns and pathways that determine who is at highest risk for progression.This publication has 10 references indexed in Scilit:
- Blood transcriptomics reveal the evolution and resolution of the immune response in tuberculosisThe Journal of Experimental Medicine, 2021
- Latent Tuberculosis: Two Centuries of ConfusionAmerican Journal of Respiratory and Critical Care Medicine, 2021
- The Epidemiological Importance of Subclinical Tuberculosis. A Critical ReappraisalAmerican Journal of Respiratory and Critical Care Medicine, 2021
- Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: A systematic review and meta-analysisPLOS ONE, 2020
- Blood transcriptional signatures for tuberculosis testingThe Lancet. Respiratory Medicine, 2020
- Host-response-based gene signatures for tuberculosis diagnosis: A systematic comparison of 16 signaturesPLoS Medicine, 2019
- The value of transcriptomics in advancing knowledge of the immune response and diagnosis in tuberculosisNature Immunology, 2018
- Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of InfectionClinical Microbiology Reviews, 2018
- A blood RNA signature for tuberculosis disease risk: a prospective cohort studyThe Lancet, 2016
- An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosisNature, 2010